Literature DB >> 27622459

Self-Assembled DNA Nanocentipede as Multivalent Drug Carrier for Targeted Delivery.

Wenshan Li1, Xiaohai Yang1, Leiliang He1, Kemin Wang1, Qing Wang1, Jin Huang1, Jianbo Liu1, Bin Wu1, Congcong Xu1.   

Abstract

An idea drug carrier, with good binding affinity, selectivity, drug payload capacity, and cellular internalized capability, will greatly improve the efficiency of target delivery. Herein a self-assembled and multivalent DNA nanostructure was developed as drug carrier for efficient and targeted delivery. The DNA structure was similar to that of a centipede, composed of trunk and legs: The trunk was a self-assembled DNA scaffold via hybridization chain reaction (HCR) from two biotinylated hairpin monomers created upon initiation by a trigger DNA, and the legs were biotinylated aptamers conjugated to the trunk via streptavidin-biotin affinity interaction. The long trunk of the "DNA nanocentipede" was loaded with doxorubicin (Dox), and the legs were SMMC-7721 cell-binding aptamers (Zy1) which functioned as targeting moieties to firmly and selectively grasp target cells. The results of agarose gel electrophoresis and fluorescence anisotropy confirmed that Zy1-based DNA nanocentipedes (Zy1-Nces) were successfully constructed. Flow cytometric analyses demonstrated that Zy1-Nces were more effective than free Zy1 in binding affinity and selectivity due to a multivalent effect. Confocal microscopy studies demonstrated that the internalization was highly dependent on the higher valences of DNA nanocentipedes without the loss of selectivity. Meanwhile, Zy1-Nces exhibited high drug-loading capacity and selective drug transport. The results of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed enhanced cellular cytotoxicity of the Dox-loaded Zy1-Nces (Zy1-Nces-Dox) to the target SMMC-7721 cells but not negative control L02 cells. This approach is applicable to prepare drug carriers for other targets by construction of the nanocentipedes with relevant nucleic acid fragments.

Entities:  

Keywords:  aptamer; cancer theranostics; multivalent; self-assembly; targeted delivery

Mesh:

Substances:

Year:  2016        PMID: 27622459     DOI: 10.1021/acsami.6b08210

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  7 in total

1.  A DNA nanowire based localized catalytic hairpin assembly reaction for microRNA imaging in live cells.

Authors:  Qiaomei Wei; Jin Huang; Jing Li; Jiaoli Wang; Xiaohai Yang; Jianbo Liu; Kemin Wang
Journal:  Chem Sci       Date:  2018-08-20       Impact factor: 9.825

Review 2.  Critical parameters for design and development of multivalent nanoconstructs: recent trends.

Authors:  Avijit Kumar Bakshi; Tanweer Haider; Rahul Tiwari; Vandana Soni
Journal:  Drug Deliv Transl Res       Date:  2022-01-11       Impact factor: 5.671

Review 3.  The biological applications of DNA nanomaterials: current challenges and future directions.

Authors:  Wenjuan Ma; Yuxi Zhan; Yuxin Zhang; Chenchen Mao; Xueping Xie; Yunfeng Lin
Journal:  Signal Transduct Target Ther       Date:  2021-10-08

Review 4.  Therapeutic Applications of Programmable DNA Nanostructures.

Authors:  Seaim Lwin Aye; Yusuke Sato
Journal:  Micromachines (Basel)       Date:  2022-02-17       Impact factor: 2.891

5.  Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.

Authors:  Fengjiao Yao; Yacong An; Xundou Li; Zhaoyi Li; Jinhong Duan; Xian-Da Yang
Journal:  Int J Nanomedicine       Date:  2020-03-27

Review 6.  DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.

Authors:  Qingjia Chi; Zichang Yang; Kang Xu; Chunli Wang; Huaping Liang
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

Review 7.  Multivalent Aptamer Approach: Designs, Strategies, and Applications.

Authors:  Zhong Wang; Xiuying Yang; Nicholas Zhou Lee; Xudong Cao
Journal:  Micromachines (Basel)       Date:  2022-03-12       Impact factor: 2.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.